ArticleCancers2022

Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments.

Leah Klingel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.